Diabetes
From the Journals
Nearly one in five U.S. adolescents have prediabetes
Prediabetes is more common in male adolescents than in female adolescents in the United States.
Conference Coverage
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
Conference Coverage
Metformin after GDM: Lessons from landmark diabetes prevention trial
WASHINGTON – Dr. Robert E. Ratner and Dr. Kim Boggess expound on the evidence base for using metformin and give their takes on postpartum clinical...
Latest News
AASLD debrief: Five drugs show promise in NAFLD (and two do not)
BOSTON – Promising new data for cotadutide, licogliflozin, tropifexor, saroglitazar, and PF-05221304 highlighted in...
Conference Coverage
Data build on cardiovascular disease risk after GDM, HDP
WASHINGTON – “The metabolic stress of pregnancy can uncover underlying susceptibilities.” – Deborah B. Ehrenthal, MD...
Conference Coverage
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
PHILADELPHIA –
Latest News
FDA panel rejects new empagliflozin indication for type 1 diabetes
Panelists voted 14-2 against the application and criticized the limited data supporting the application.
Conference Coverage
New model for CKD risk draws on clinical, demographic factors
The equation has demonstrated high discrimination and variable calibration across a range of populations.
From the Journals
Vitamin D, omega-3 fatty acids do not preserve kidney function in type 2 diabetes
After 5 years of follow-up, the supplements showed no significant difference in change in eGFR, compared with placebo.
Conference Coverage
Duodenal mucosal resurfacing has metabolic effects in type 2 diabetes
BOSTON – Improvements in HbA1c and NASH biomarker favored the procedure over sham procedure in first-ever randomized, double-blind...
Latest News
Cardiometabolic risk burden is high in under-50s with type 2 diabetes
BARCELONA – Younger people with type 2 diabetes need a more focused treatment strategy, irrespective of cardiometabolic risk.